Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma

• Published in: Frontiers in medicine Vol. 9; p. 939776
• Main Authors: Lu, Hanwen, Zhou, Liwei, Zhang, Bingchang, Xie, Yuanyuan, Yang, Huiyin, Wang, Zhanxiang
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 29.11.2022
• Subjects: Cuproptosis; glioma; immune infiltration; lipoylation; Medicine; prognostic biomarker; glioma; prognostic biomarker; immune infiltration; Cuproptosis; lipoylation
• ISSN: 2296-858X; 2296-858X
• DOI: 10.3389/fmed.2022.939776

Recent studies have found that the protein encoded by the FDX1 gene is involved in mediating Cuproptosis as a regulator of protein lipoylation and related to immune response process of tumors. However, the specific biological function of FDX1 in glioma is currently unclear. To explore the potential function of FDX1 , this study explored the correlation between the expression of FDX1 in cancers and survival prognosis by analyzing the public databases of GEPIA and Cbioportal. Immune infiltration was analyzed by the TIMER2.0 database in tumors. The possible biological processes and functions of FDX1-related in glioma were annotated through gene enrichment. Relationship between Cuproptosis and autophagy was explored through gene co-expression studies. Summary and conclusions of this study: (1) FDX1 is highly expressed in gliomas and associated with poor prognosis in low-grade gliomas (LGG). (2) Gene annotation indicates that FDX1 is mainly involved in the tumor protein lipoylation and cell death. (3) FDX1 expression is positively correlated with the infiltration of immune cells. (4) LIPT2 and NNAT , two other genes involved in lipoylation, may be unidentified marker gene for Cuproptosis. And the Cuproptosis genes related to FDX1 were positively correlated with the expression of autophagy marker genes Atg5 , Atg12 , and BECN-1 . This evidence suggests that there may be some interaction between FDX1 mediated Cuproptosis and autophagy. In summary, FDX1 may serve as a potential immunotherapy target and prognostic marker for Glioma.